Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:46 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:46 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
by Zacks Equity Research
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
by Zacks Equity Research
Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $9.97, moving +1.73% from the previous trading session.
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up
by Zacks Equity Research
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
by Zacks Equity Research
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US
by Zacks Equity Research
Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA
by Zacks Equity Research
The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
by Zacks Equity Research
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
5 Low Price-to-Book Stocks to Buy in November
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Teva (TEVA) Q3 Earnings Miss, Sales Top Estimates, Stock Up
by Zacks Equity Research
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. Shares rise in pre-market trading.
Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.15 in the latest trading session, marking a -0.49% move from the prior day.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.03, moving -1.65% from the previous trading session.
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
by Zacks Equity Research
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Q3 Earnings Reports to Flood Wall Street This Week
by Zacks Equity Research
Q3 Earnings Reports to Flood Wall Street This Week
Opioid Settlement, Boeing Downgrades: Markets Looking Up
by Mark Vickery
Futures are up somewhat in this Monday's pre-market after a sell-off Friday. Much of the sentiment going forward will rely on Q3 results and other news items.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
by Zacks Equity Research
J&J (JNJ) comes up with encouraging third-quarter 2019 results.